Literature DB >> 15534444

Metformin in polycystic ovary syndrome.

Jonathan Lord1, Terry Wilkin.   

Abstract

PURPOSE OF REVIEW: Metformin has become an established treatment for women with polycystic ovary syndrome, although controversy remains as to how effective it is and in which populations it should be used. This review examines the recent literature in order to ascertain the evidence for the benefits and disadvantages of using metformin in women with polycystic ovary syndrome. RECENT
FINDINGS: A Cochrane systematic review and metaanalysis examined the evidence for metformin in treating polycystic ovary syndrome. Since this was published there have been a number of new trials, some of which have been reasonably large involving participants from many different countries.
SUMMARY: Evidence shows that metformin is effective in inducing ovulation, has some marginal benefit in improving aspects of the metabolic syndrome, improves objective measures of hirsutism, and seems to be effective in both obese and lean individuals. However, it has significant side effects, and the high levels of effectiveness that were reported by some early trials have not been replicated. Metformin should always be used as an adjuvant to general lifestyle improvements, and not as a replacement for increased exercise and improved diet.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534444     DOI: 10.1097/00001703-200412000-00008

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  10 in total

1.  Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.

Authors:  Fuhai Hui; Yingshi Zhang; Tianshu Ren; Xiang Li; Mingyi Zhao; Qingchun Zhao
Journal:  Eur J Clin Pharmacol       Date:  2018-12-03       Impact factor: 2.953

2.  Drugs for anovulatory infertility in polycystic ovary syndrome.

Authors:  Hesham Al-Inany; Neil Johnson
Journal:  BMJ       Date:  2006-06-24

3.  A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity.

Authors:  Hasan Rezvanian; Mahin Hashemipour; Roya Kelishadi; Naser Tavakoli; Parinaz Poursafa
Journal:  World J Pediatr       Date:  2010-11-16       Impact factor: 2.764

4.  Role of Oxidative Stress in Obese and Nonobese PCOS Patients.

Authors:  Kazım Uçkan; Halit Demir; Kasım Turan; Eren Sarıkaya; Canan Demir
Journal:  Int J Clin Pract       Date:  2022-02-09       Impact factor: 3.149

5.  Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3.

Authors:  Wendy Chang; Mark O Goodarzi; Heith Williams; Denis A Magoffin; Marita Pall; Ricardo Azziz
Journal:  Fertil Steril       Date:  2008-01-07       Impact factor: 7.329

6.  Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes.

Authors:  Deborah L Kendall; Rakesh Amin; Peter E Clayton
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

7.  Effects of Treatment on Endocrine Function in Patients with Epilepsy.

Authors:  Alison Pack
Journal:  Curr Treat Options Neurol       Date:  2005-07       Impact factor: 3.972

8.  Metformin lowers serum cobalamin without changing other markers of cobalamin status: a study on women with polycystic ovary syndrome.

Authors:  Eva Greibe; Birgitta Trolle; Mustafa V Bor; Finn F Lauszus; Ebba Nexo
Journal:  Nutrients       Date:  2013-07-05       Impact factor: 5.717

9.  Changing prostaglandin E2 (PGE2) signaling during lesional progression and exacerbation of endometriosis by inhibition of PGE2 receptor EP2 and EP4.

Authors:  Qingqing Huang; Xishi Liu; Sun-Wei Guo
Journal:  Reprod Med Biol       Date:  2021-12-02

Review 10.  Metformin as a Potential Treatment Option for Endometriosis.

Authors:  Żaneta Kimber-Trojnar; Dominik Franciszek Dłuski; Magdalena Wierzchowska-Opoka; Monika Ruszała; Bożena Leszczyńska-Gorzelak
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.